What is the recommended treatment approach for an adult patient with overlapping bullous pemphigoid and porphyria (e.g., porphyria cutanea tarda)?

Treatment of Overlapping Bullous Pemphigoid and Porphyria

For a patient with both bullous pemphigoid and porphyria cutanea tarda, treat the bullous pemphigoid with superpotent topical corticosteroids (clobetasol propionate 0.05%) while simultaneously managing the porphyria with phlebotomy or low-dose chloroquine, avoiding systemic corticosteroids if possible to prevent exacerbation of the porphyria.

Algorithmic Treatment Approach

Step 1: Confirm Both Diagnoses

• Bullous pemphigoid: Direct immunofluorescence showing linear IgG/C3 at basement membrane zone, anti-BP180/BP230 antibodies 1
• Porphyria cutanea tarda: Elevated urinary uroporphyrins and heptacarboxyl porphyrins, plasma fluorescence scanning 2

Step 2: Prioritize Topical Therapy for BP

For localized or limited BP with concurrent PCT:

• Clobetasol propionate 0.05% cream/ointment applied directly to lesions only (not whole body) 1
• This minimizes systemic absorption while controlling blistering
• Avoid extensive whole-body application (30-40g/day) that would be standard for extensive BP, as this increases systemic steroid exposure

For extensive BP requiring more aggressive treatment:

• Start with superpotent topical corticosteroids on affected areas 1
• If inadequate control, consider oral corticosteroids as second-line, but use the lowest effective dose and shortest duration possible
• The European Dermatology Forum guidelines establish topical clobetasol as level 1 validated evidence for extensive BP 1

Step 3: Simultaneously Treat the Porphyria

First-line PCT treatment options:

• Phlebotomy: 450 mL every 1-2 weeks until ferritin normalizes 3

  • This is the safest option when combined with BP treatment
  • No drug interactions with topical corticosteroids
  • One case report demonstrated that phlebotomy for PCT improved concurrent ocular cicatricial pemphigoid, suggesting potential benefit for overlapping autoimmune blistering conditions 4

• Low-dose chloroquine: 125 mg twice weekly 3

  • Effective for porphyrin elimination
  • Use cautiously as it may theoretically affect immune-mediated processes

Avoid high-dose antimalarials initially, as these can trigger or worsen bullous eruptions in some contexts 5

Step 4: Address Triggering Factors

For PCT:

• Discontinue alcohol consumption 3
• Stop estrogens, iron supplements if applicable 3
• Screen for hepatitis C, hemochromatosis, diabetes 6, 3

For BP:

• Review medications (diuretics, antibiotics, antihypertensives) that may trigger BP
• Assess for malignancy in elderly patients 1

Step 5: Monitoring and Tapering

BP monitoring:

• Disease control = no new lesions or pruritus, established lesions healing 1
• Begin tapering topical steroids 15 days after disease control 1
• Tapering schedule: daily → every 2 days (month 2) → twice weekly (month 3) → once weekly (month 4+) 1

PCT monitoring:

• Check urinary porphyrins every 2-3 months
• Continue phlebotomy until ferritin <50 ng/mL and porphyrins normalize 3

Critical Caveats and Pitfalls

Avoid systemic immunosuppression if possible: While azathioprine, mycophenolate, or high-dose oral corticosteroids are standard second-line agents for BP 1, these may complicate PCT management and increase infection risk. The topical approach is particularly advantageous in this overlap scenario.

Photosensitivity considerations: Both conditions involve photosensitivity. Strict photoprotection (broad-spectrum sunscreen, protective clothing, avoid sun 10am-4pm) is essential for PCT and won't harm BP management.

The rare but documented association: While only one case report directly documents improvement of cicatricial pemphigoid with PCT treatment 4, this suggests potential mechanistic overlap. Treating the PCT may provide additional benefit beyond just managing two separate conditions.

Renal function matters: If the patient has renal impairment, phlebotomy becomes more challenging and chloroquine dosing requires adjustment 3. Consider erythropoietin or desferrioxamine in dialysis patients 3.

When Systemic Therapy Becomes Necessary

If topical therapy fails to control BP after 1-3 weeks at maximum doses (40g/day clobetasol) 1:

• Oral prednisone 0.5-0.75 mg/kg/day is the validated systemic option 1
• Accept that this may temporarily worsen PCT photosensitivity
• Intensify PCT treatment (more frequent phlebotomy) to compensate
• Taper steroids aggressively once BP control achieved

Dapsone (listed as third-line for BP 1) should be avoided or used with extreme caution, as it can precipitate porphyria attacks in some porphyria types, though this is less documented in PCT specifically.

The key principle is treating both conditions simultaneously with the least overlapping toxicity, favoring topical over systemic approaches whenever feasible, and recognizing that successful PCT management may provide unexpected benefits for the autoimmune blistering component 4.